Beta Bionics, Inc. (NASDAQ:BBNX) Receives $20.10 Average Price Target from Analysts

Beta Bionics, Inc. (NASDAQ:BBNX) has been given a consensus rating of “Moderate Buy” by the eleven ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $20.10.

Several equities analysts recently issued reports on the stock. Bank of America cut their price objective on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. Stifel Nicolaus dropped their target price on Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. UBS Group assumed coverage on Beta Bionics in a report on Tuesday, July 28th. They issued a “buy” rating and a $22.00 price target on the stock. The Goldman Sachs Group boosted their price target on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Finally, Truist Financial upped their price objective on Beta Bionics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, July 13th.

Insider Buying and Selling

In other Beta Bionics news, insider Steven Jon Russell sold 4,222 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total value of $53,239.42. Following the completion of the transaction, the insider directly owned 173,849 shares in the company, valued at approximately $2,192,235.89. The trade was a 2.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Christy Jones sold 2,811 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $14.00, for a total transaction of $39,354.00. Following the sale, the director directly owned 27,400 shares of the company’s stock, valued at approximately $383,600. The trade was a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 40,351 shares of company stock valued at $553,961 over the last three months. Corporate insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Beta Bionics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its position in shares of Beta Bionics by 0.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock worth $10,105,000 after purchasing an additional 931 shares in the last quarter. Deutsche Bank AG increased its position in Beta Bionics by 3.4% during the 4th quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock valued at $1,197,000 after buying an additional 1,296 shares in the last quarter. Summit Securities Group LLC purchased a new stake in Beta Bionics in the fourth quarter valued at about $52,000. Caitong International Asset Management Co. Ltd raised its stake in Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after buying an additional 1,818 shares during the last quarter. Finally, Verition Fund Management LLC boosted its holdings in Beta Bionics by 4.0% in the third quarter. Verition Fund Management LLC now owns 47,299 shares of the company’s stock worth $940,000 after acquiring an additional 1,823 shares in the last quarter.

Beta Bionics Price Performance

Shares of Beta Bionics stock opened at $13.91 on Monday. The stock has a market cap of $625.81 million, a price-to-earnings ratio of -8.43 and a beta of 3.13. The firm’s 50-day moving average is $15.12 and its two-hundred day moving average is $13.11. Beta Bionics has a 1 year low of $8.80 and a 1 year high of $32.71.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The business had revenue of $32.01 million during the quarter. On average, equities analysts expect that Beta Bionics will post -2.1 earnings per share for the current year.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.